Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2016)

Historic Preferred Stock Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 2 years, with Q4 2016 value amounting to $77.0 million.

  • Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities rose 2650.12% to $77.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $77.0 million, marking a year-over-year increase of 2650.12%. This contributed to the annual value of $77.0 million for FY2016, which is 2650.12% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Preferred Stock Liabilities of $77.0 million as of Q4 2016, which was up 2650.12% from $60.8 million recorded in Q4 2015.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities ranged from a high of $77.0 million in Q4 2016 and a low of $60.8 million during Q4 2015